Lindbrook Capital’s Ovid Therapeutics OVID Stock Holding History

Lindbrook Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,000	Closed	-$15K	–	1822
2020 Q2	$15K	Buy	+2,000	New	+$9.36K	﹤0.01%	716

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Lindbrook Capital's OVID Position: Q3 2020 in Review

Lindbrook Capital sold out of Ovid Therapeutics (OVID) in Q3 2020, closing a stake of 2,000 shares — an estimated $15K sold.

Lindbrook Capital first reported a position in OVID in Q2 2020 and held it in 1 quarter. The position peaked at $15K in Q2 2020. 91 funds tracked by Wall St. Rank hold OVID as of Q3 2020.

Lindbrook Capital reported no remaining Ovid Therapeutics position as of Q3 2020 after selling out during the quarter.
Lindbrook Capital sold 2,000 Ovid Therapeutics shares in Q3 2020, an estimated $15K.
Lindbrook Capital first reported a position in Ovid Therapeutics in Q2 2020 and held it in 1 quarter.
Lindbrook Capital's Ovid Therapeutics position peaked at $15K in Q2 2020.
91 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2020.

Based on Lindbrook Capital's 13F filing for Q3 2020, filed 3 Nov 2020.